Compare Amphastar Pharmaceuticals Inc (AMPH) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs KLA Corp. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while KLA Corp. trades at $202.5 (market cap $251.82B). The key difference: KLA Corp. is far larger — about 291.5× Amphastar Pharmaceuticals Inc's market cap, and KLA Corp. pays a 0.48% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KLAC | |
|---|---|---|
Market Cap | $863.95M | $251.82B |
Sector | Health | Technology |
52-Week High | $30.81 | $301.71 |
52-Week Low | $16.87 | $84.39 |
Enterprise Value | $1.26B | $253.07B |
Dividend Yield | — | 0.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
KLA Corporation (KLAC) trades at $198.11, up 2.53% today, with a neutral technical signal despite bullish moving averages. The stock shows strong fundamentals, including a 35.57% net income margin and consistent earnings beats, with Q3 2026 EPS expected at $1.17. Recent corporate actions include a 1:10 stock split and a $2.30 dividend, while cash flow remains positive at $101.78M in 2025. Analyst sentiment is optimistic, with a $246.93 consensus price target implying significant upside.
The outlook for KLAC is positive, driven by AI-driven semiconductor demand and robust profitability, but risks include high valuation multiples and market volatility. Investment opportunities center on growth in advanced packaging, with Wall Street largely bullish; however, investors should monitor competitive pressures and economic cycles that could impact the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
